title: FK506 inhibition of histamine release and cytokine production by mast cells and basophils.
abstract: Histamine release and cytokine production by mast cells and basophils are thought to be closely involved in the pathogenesis of allergic diseases. Some reports show that FK506 (tacrolimus hydrate) inhibited histamine release and cytokine production by mast cells and basophils. However, as the effects of FK506 has not been compared with those of clinically used drugs in those reports, the clinical relevancy of FK506 inhibition remained unclear. In this paper, we compared the actions of FK506 with those of steroids or disodium cromoglycate (DSCG) which has been clinically used. FK506 inhibited histamine release by Brown-Norway rat peritoneal mast cells more potently than steroids and especially DSCG. FK506 also inhibited histamine release by a mast rat basophilic leukemia (RBL)-1 cell line and human peripheral blood basophils, whereas steroids failed to inhibit histamine release by human basophils. FK506 as well as steroids inhibited TNF-alpha and IL-4 production by RBL-1 cells. FK506 was therefore more effective than steroids and DSCG in inhibiting histamine release, and it also had the ability of inhibiting cytokine production by mast cells as steroids do. We concluded that FK506 might regulate allergic diseases via these actions, judging from the viewpoint of clinical relevancy.
authors.affiliation: Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., 1-6, 2-chome, Kashima, Yodogawa-ku, Osaka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Sengoku
authors.forename: S
authors.initials: S
authors.lastname: Kishi
authors.forename: S
authors.initials: S
authors.lastname: Sakuma
authors.forename: Y
authors.initials: Y
authors.lastname: Ohkubo
authors.forename: T
authors.initials: T
authors.lastname: Goto
mesh_terms: D000818:Animals; D001491:Basophils / Q000187:drug effects* / Q000378:metabolism; D016207:Cytokines / Q000096:biosynthesis*; D006636:Histamine Release / Q000187:drug effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D015847:Interleukin-4 / Q000096:biosynthesis; D008297:Male; D008407:Mast Cells / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D011914:Rats, Inbred BN; D016559:Tacrolimus / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D016207:Cytokines; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D015847:Interleukin-4; D016559:Tacrolimus